利民股份(002734.SZ):控股子公司新威遠取得環評批覆
格隆匯5月29日丨利民股份(002734.SZ)公佈,近日,公司控股子公司內蒙古新威遠生物化工有限公司(“新威遠”)取得《鄂爾多斯生態環境局關於新威遠生物化工有限公司新型綠色生物產品製造項目環境影響報告書的批覆》(鄂環審字[2020]163號)。
該批覆同意新威遠在鄂爾多斯市達拉特旗經濟開發區三垧梁園區建設500T多殺菌素、500T泰樂菌素、500T截短側耳素等項目,並且落實批覆中提出的各項環保要求,嚴格執行環保“三同時”制度,確保各類污染物穩定達標排放。項目總投資預計10.395億元,其中環保投資預計2.2655億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.